NCT05501769View on ClinicalTrials.gov

ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 8, 2022

Primary Completion Date

July 3, 2024

Study Completion Date

August 25, 2025

Conditions
Breast Cancer
Interventions
DRUG

ARV-471 in combination with Everolimus

ARV-471 oral tablets in combination with everolimus administered daily in 28 day cycles

Trial Locations (9)

20007

Clinical Trial Site, Washington D.C.

28034

Clinical Trial Site, Madrid

32746

Clinical Trial Site, Lake Mary

37203

Clinical Trial Site, Nashville

46018

Clinical Trial Site, Valencia

48109

Clinical Trial Site, Ann Arbor

90404

Clinical Trial Site, Santa Monica

92037

Clinical Trial Site, San Diego

08028

Clinical Trial Site, Barcelona

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Arvinas Estrogen Receptor, Inc.

INDUSTRY

NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer | Biotech Hunter | Biotech Hunter